Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.3352W HIGH $9.04
Volume
241.52 K
Value Traded
17.90 M
Short % Float
2.49%
Days to Cover
4.2
+29.13%Week
+39.22%1 Month
+17.14%3 Month
+48.28%6 Month
-82.79%5 Year
+994.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.08 B
EPS (TTM)
-2.25
P/E Ratio
-
Ent. Value
22.09 B
Total Shares
374.02 M
Float Shares
331.34 M
Insiders
11.40%
Institutions
63.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BHC Catalyst Timeline
Dated clinical, regulatory and corporate events for Bausch Health Companies Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bausch Health Companies Inc.
298Total events
2Upcoming
85Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Corporate ApprovalCorporate
Board of Directors authorized US$50 million share repurchase program
●Poster PresentationPresentation
Poster presentation of 6-month cirrhosis clinical pathway pilot study results at ACG 2026
cirrhosissource ↗
▲Partnership / LicenseCorporate
Bausch Health and YUN expand strategic collaboration to Mexico and additional EMEA markets
▲Other Regulator MilestoneThermageEx-US Regulatory
Thermage awarded AAA Well-Known Trademark Certification in China
non-invasive skin tighteningsource ↗
◆R&D DayPresentation
Bausch Health to participate in RBC Capital Markets 2026 Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Bausch Health management to participate in fireside chat at Barclays 30th Annual Leveraged Finance Conference
●Quarterly UpdateCorporate
Reaffirmed full-year 2026 guidance for Bausch Health excluding Bausch + Lomb
●Pipeline PrioritizationLarsucosterolCorporate
Larsucosterol Phase 3 program for alcohol-associated hepatitis remains on track
alcohol-associated hepatitissource ↗
▲Product LaunchBiafinePost-Market
Biafine Skin Recovery Emulsion launched for online ordering in the US
dry, sensitive, or stressed skinsource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and conference call
▲Breakthrough Therapy DesignationLarsucosterolDesignation
FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
Alcohol-Associated Hepatitissource ↗
▼Primary Endpoint MissedrifaximinApprovedClinical Data
RED-C Phase 3 trials did not meet primary endpoint
primary prevention of hepatic encephalopathy in adults with liver cirrhosissource ↗
◆R&D DayPresentation
Bausch Health CEO to present at 44th Annual J.P. Morgan Healthcare Conference
▲First Patient DosedLarsucosterolTrial
First patient randomized in Phase 3 trial of Larsucosterol
Alcohol-Associated Hepatitissource ↗
◆Topline ReadoutRED-CClinical Data
Top-line Phase 3 results for RED-C expected
prevention and delay of first episode of overt hepatic encephalopathysource ↗
▲Product LaunchPost-Market
YUN probiotic skin care products launched in Czech Republic, Slovakia, Ukraine and Bulgaria
acne-prone skin and eczema-prone skinsource ↗
▲Product LaunchYUNPost-Market
YUN probiotic skincare products launched in Czech Republic, Slovakia, Ukraine and Bulgaria
acne-prone skin and eczema-prone skin skincaresource ↗
▲Runway Guidance UpdateCorporate
Raises full year 2026 Revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance
◆Debt Royalty FinancingCorporate
Exchange offers for 4.875% and 11.00% Senior Secured Notes expired
▲Australia ApprovalEx-US Regulatory
Fraxel FTX fractional laser system received approval in Australia
skin rejuvenationsource ↗
▲Partnership / LicenseCorporate
Completed acquisition of Shibo's full service aesthetics distribution business in China
▲Quarterly UpdateCorporate
Raised full-year 2025 guidance for Revenue, Adjusted EBITDA, and Adjusted Cash Flow from Operations
◆AcquisitionLarsucosterolCorporate
Completed acquisition of DURECT Corporation, adding Larsucosterol
alcohol-associated hepatitissource ↗
▲Breakthrough Therapy DesignationLarsucosterolDesignation
FDA Breakthrough Therapy Designation for Larsucosterol in AH
alcohol-associated hepatitissource ↗
▲China ApprovalClearApprovedEx-US Regulatory
Clear + Brilliant Touch received approval from Chinese NMPA
skin resurfacingsource ↗
●EU MAA SubmissionCabtreoApprovedEx-US Regulatory
CABTREO submitted for approval with EMA (EU)
acne vulgarissource ↗
◆Management ChangeCorporate
Appointment of Michael Goettler and Sandra Leung to Board of Directors
◆Management ChangeCorporate
Appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer
◆AcquisitionCorporate
Agreement to acquire DURECT Corporation for alcohol-induced hepatitis treatment
alcohol-induced hepatitissource ↗
●EU MAA SubmissionCabtreoApprovedEx-US Regulatory
CABTREO submitted for approval with EMA (EU)
acne vulgarissource ↗
▲IP Litigation RulingIP / Competition
Favorable ruling from D.C. District Court in Norwich's case against the FDA
▲Other Regulator MilestoneEx-US Regulatory
Medical device license clearance granted by Health Canada for Thermage FLX
skin tightening and texture improvementsource ↗
▲Product LaunchPost-Market
Fraxel FTX fractional laser system launched in the U.S.
skin rejuvenation, sun damage, wrinkles, acne scars, pigmentation irregularitiessource ↗
●Trial InitiationRED-CTrial
Both global Phase 3 studies for RED-C in treatment phase
prevention and delay of first episode of overt hepatic encephalopathysource ↗
▼Program DiscontinuationAmiselimodDiscontinuedCorporate
Phase 2 study for Crohn's disease will not proceed
Crohn's diseasesource ↗
▲Debt Royalty FinancingCorporate
Financing commitment for up to $700 million senior secured credit facility entered
Past FDA Catalysts and PDUFA Decisions
How BHC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-10-20 | Cabtreo (adapalene) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 8%
Small Cap(rank 55 of 674)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Devices | |||
| Over the Counter Products | |||
| Price Appreciation Credit |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Larsucosterol Small moleculeNCT07428538 | Hepatitis | Phase 3 | RECRUITING | 350 | Feb 1, 2028 | ||||||
| plecanatide Small moleculeNCT07723924 | Functional Constipation (FC) | Phase 2 | ACTIVE NOT_RECRUITING | 180 | Oct 18, 2027 | ||||||
| BL1107 Small moleculeNCT07778888 | Dry Eye Disease | Phase 2 | NOT YET_RECRUITING | 20 | Feb 1, 2027 | ||||||
| Rifaximin SSD Small moleculeMarketedNCT05071716 | Hepatic Encephalopathy | Approved | ACTIVE NOT_RECRUITING | 1,041 | Sep 1, 2025 | ||||||
| Cabtreo Small moleculeMarketedNCT05582434 | Acne | Approved | ACTIVE NOT_RECRUITING | 72 | Nov 1, 2026 | ||||||
| plecanatide Small moleculeMarketedNCT01722318 | Irritable Bowel Syndrome Characterized by Constipation | Approved | COMPLETED | 2,617 | Oct 1, 2014 | ||||||
| plecanatide Small moleculeMarketedNCT03120520 | Chronic Idiopathic Constipation | Approved | COMPLETED | 6,249 | Sep 7, 2018 | ||||||
| plecanatide Small moleculeMarketedNCT02706483 | Irritable Bowel Syndrome | Approved | COMPLETED | 2,272 | Jun 1, 2017 | ||||||
| plecanatide Small moleculeMarketedNCT03596905 | Irritable Bowel Syndrome With Constipation | Approved | COMPLETED | 218 | Nov 25, 2024 | ||||||
| Low Dose MT-1303 Small moleculeCompletedNCT04857112 | Ulcerative Colitis | Phase 2 | COMPLETED | 322 | Nov 8, 2024 | ||||||
| BL1332 eye Small moleculeCompletedNCT07717918 | Undisclosed | Phase 1 | COMPLETED | 28 | Aug 5, 2026 | ||||||
| Brodalumab Monoclonal antibodyNot countedNCT02024646 | Psoriatic Arthritis | Phase 3 | COMPLETED | 484 | Oct 1, 2015 | ||||||
| IDP-122 Small moleculeMarketedNCT02515097 | Plaque Psoriasis | Approved | COMPLETED | 430 | Mar 15, 2017 | ||||||
| IDP-126 Small moleculeMarketedNCT03653403 | Acne Vulgaris | Approved | COMPLETED | 1,851 | Jun 19, 2019 | ||||||
| IDP-123 Small moleculeMarketedNCT02938494 | Acne Vulgaris | Approved | COMPLETED | 1,824 | Sep 1, 2016 | ||||||
| rifaximin Small moleculeNot countedNCT00269399 | Clostridium Infections | Phase 3 | COMPLETED | 237 | Dec 1, 2008 | ||||||
| rifaximin Small moleculeNot countedNCT00724126 | Non-Constipation Irritable Bowel Syndrome | Phase 3 | COMPLETED | 1,260 | Sep 1, 2009 | ||||||
| Methylnaltrexone Small moleculeMarketedNCT00936884 | Constipation | Approved | COMPLETED | 50 | Nov 1, 2013 | ||||||
| rifaximin Small moleculeMarketedNCT00298038 | Hepatic Encephalopathy | Approved | COMPLETED | 621 | Aug 15, 2008 | ||||||
| rifaximin Small moleculeMarketedNCT01543178 | Irritable Bowel Syndrome With Diarrhea | Approved | COMPLETED | 2,583 | Jun 1, 2014 | ||||||
| Granulated mesalamine Small moleculeMarketedNCT00767728 | Ulcerative Colitis | Approved | COMPLETED | 561 | Oct 1, 2007 | ||||||
| Budesonide MMX Small moleculeMarketedNCT00679380 | Ulcerative Colitis | Approved | COMPLETED | 1,657 | Apr 1, 2010 | ||||||
| Budesonide Small moleculeMarketedNCT01100112 | Colitis, Ulcerative | Approved | COMPLETED | 61 | Aug 1, 2010 | ||||||
| Budesonide Small moleculeNot countedNCT01008423 | Proctitis | Phase 3 | COMPLETED | 546 | Mar 18, 2013 | ||||||
| Omeprazole bicarbonate immediate release PWD/FS Small moleculeMarketedNCT00045799 | Upper Gastrointestinal Bleeding | Approved | COMPLETED | 354 | May 1, 2003 |
Clinical Trial Results
Readouts, endpoints and source filings for every BHC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lenar Aimee J.Officer (President, US Pharma) | Sell | -36,827 334,853 held | $7.03 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BHC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % (50 %) | 8.38 M | 1.30 M | 76.43% ( 563.17 K) |
Ownership Trends
BHC Short Interest
Shares sold short, counted twice a month.
2.49%
Short % of Float
of tradable shares sold short
8.2M
Shares Sold Short
-1.9% vs prior count
4.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BHC ranks across every disease it competes in
Competitive Position is a premium feature
See how BHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBHC News
BHC▲ +28.8%on this news
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health Companies Inc. announced the redemption of approximately $643 million of its 8.500% Senior Notes due 2027. The redemption notice will be issued on October 29, 2026, with the redemption date set for November 30, 2026. This move is part of the company's strategy to improve its financial position.
Read more →BHC▲ +28.8%on this newsshared move
Bausch Health Announces US$50 Million Share Repurchase Program
Bausch Health Companies Inc. announced a US$50 million share repurchase program authorized by its Board of Directors. The program aims to mitigate the dilutive effects of future employee equity compensation. Purchases may start on November 3, 2026, and will conclude by November 3, 2027, depending on market conditions.
Read more →BHC▲ +9.7%on this news· ran to +41% by day 1shared move
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Bausch Health reported third quarter 2026 revenues of $2.94 billion, a 10% increase from the previous year. The company achieved a net income of $436 million and adjusted EBITDA of $1,305 million, marking a 32% year-over-year growth. Bausch Health raised its full year guidance, reflecting strong operational performance and cash generation.
Read more →BHCSix-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Bausch Health Companies Inc. announced positive results from a six-month pilot study on a standardized clinical pathway for cirrhosis management. The study showed improved adherence to guideline-recommended practices across five community gastroenterology practices. Key performance indicators demonstrated significant improvements in patient care metrics, suggesting the pathway's feasibility and effectiveness in enhancing treatment adherence.
Read more →BHCBausch Health to Announce Third Quarter 2026 Results on October 28, 2026
Bausch Health Companies Inc. will announce its third quarter 2026 financial results on October 28, 2026. The announcement will be followed by a live conference call and webcast at 5:00 p.m. U.S. EDT. Investors can access all relevant materials on the company's Investor Relations website prior to the call.
Read more →BHC(Pr)SILIQ® (brodalumab injection) Now Reimbursed Under Alberta's Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis
Bausch Health announced that SILIQ® (brodalumab injection) is now reimbursed under Alberta's public drug plan, enhancing access for eligible patients with moderate to severe plaque psoriasis. This decision marks a significant step towards comprehensive coverage across Canada. Experts emphasize the importance of timely treatment for improving patients' quality of life. However, concerns remain regarding potential side effects associated with the medication.
Read more →BHCBausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
Bausch Health and YUN have announced an expansion of their collaboration to introduce microbiome-friendly skincare solutions in Mexico and several EMEA markets, including the Czech Republic, Slovakia, Ukraine, Bulgaria, and Kazakhstan. This strategic partnership aims to enhance access to innovative dermatological products, building on previous launches in Poland. Both companies emphasize their commitment to science-led healthcare solutions.
Read more →BHCBausch Health a YUN oznamují expanzi do Mexika a na nové trhy v regionu EMEA
Bausch Health Companies Inc. and YUN have announced an expansion into Mexico and several EMEA markets, including the Czech Republic, Slovakia, Ukraine, Bulgaria, and Kazakhstan. This collaboration aims to enhance access to scientifically developed skincare products that are gentle on the skin microbiome. The expansion follows a successful entry into Poland and reflects both companies' commitment to providing innovative dermatological solutions.
Read more →BHCBausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
Bausch Health has announced the launch of Fraxel FTX in Australia, starting September 1, 2026. This next-generation skin resurfacing technology aims to improve treatment precision and patient comfort. Fraxel FTX incorporates dual wavelengths for targeted treatment and features enhancements for ease of use. The company also emphasizes support for practitioners through education and training.
Read more →BHCBausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
Bausch Health's Ortho Dermatologics has announced the winners of its 2026 Aspire Higher Scholarship Program, awarding six students affected by dermatologic conditions. Each recipient will receive up to $10,000 to support their studies. The program, which has awarded over $1 million since its inception in 2013, aims to recognize and support students' educational journeys.
Read more →BHCBausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
Bausch Health has announced the winners of its 2026 Salix Gastrointestinal Health Scholars Program, awarding $10,000 scholarships to ten students living with gastrointestinal diseases. This initiative, now in its seventh year, recognizes the resilience and ambition of these students in pursuing higher education. The recipients were selected from over 450 applicants and shared powerful reflections on how the scholarship supports their academic journeys.
Read more →BHC▼ -6%on this news
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Bausch Health's CEO, Thomas J. Appio, has been appointed to the board of Bausch + Lomb, effective August 5, 2026. This change is part of a board restructuring that includes the addition of three new directors. Bausch Health, holding 87% of Bausch + Lomb's shares, aims to support its subsidiary's long-term growth objectives.
Read more →BHCBAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
Bausch Health Companies Inc. reported strong financial results for the second quarter of 2026, with consolidated revenues of $2.85 billion, marking a 13% increase compared to the previous year. The company achieved a net income of $258 million and raised its full-year guidance for revenue and adjusted EBITDA. This marks the thirteenth consecutive quarter of revenue growth, driven by robust performance across various segments.
Read more →BHCBausch Health to Announce Second Quarter 2026 Results on July 29, 2026
Bausch Health Companies Inc. will release its second quarter 2026 financial results on July 29, 2026, after market close. A live conference call and webcast will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. The materials will be available on the Investor Relations section of their website prior to the call.
Read more →BHCMichael Goettler Resigns from Bausch Health's Board of Directors
Michael Goettler has resigned from Bausch Health's Board of Directors effective June 30, 2026, to assume the role of President and CEO at Knoa Pharma LLC. His departure was amicable and not due to any disagreements regarding the company's operations. Bausch Health expressed appreciation for his contributions during his tenure.
Read more →BHCBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Solta Medical has achieved the AAA Well-Known Trademark Certification for Thermage® in China, a significant recognition awarded to only 217 brands. This certification underscores Thermage's strong brand reputation and consumer confidence in the non-invasive aesthetic treatment market. The CEO highlighted this achievement as a testament to their commitment to quality and innovation.
Read more →BHCBausch Health Announces 2026 Annual Meeting of Shareholder Results
Bausch Health Companies Inc. announced the successful election of all 10 director nominees during its 2026 Annual Meeting of Shareholders. Notably, Dr. Eiry W. Roberts was elected as a new director, bringing extensive experience in pharmaceutical leadership. Shareholders also approved the compensation for named executive officers and the appointment of PricewaterhouseCoopers LLP as the auditor.
Read more →BHCBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
Bausch Health Companies Inc. will participate in the RBC Capital Markets 2026 Global Healthcare Conference on May 20, 2026. CEO Thomas J. Appio and CFO Jean-Jacques Charhon will engage in a fireside chat, which will be available via a live audio webcast. A replay will also be accessible post-event.
Read more →BHCBausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
Bausch Health Companies Inc. will participate in the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026. Company management will engage in a fireside chat, which will be accessible via a live audio webcast. A replay will also be available post-event, emphasizing the company's commitment to investor relations.
Read more →BHCBAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
Bausch Health Companies Inc. announced its financial results for the first quarter of 2026, reporting consolidated revenues of $2.52 billion, a 12% increase from the prior year. However, the company experienced a significant GAAP net loss of $1,423 million, largely due to a substantial goodwill impairment charge. Despite these losses, Bausch Health marked its twelfth consecutive quarter of revenue growth and a 32% increase in adjusted earnings per share. The company reaffirmed its full-year guidance while focusing on strategic investments in its pipeline.
Read more →About Bausch Health Companies Inc.
Headquarters2150 ST. ELZEAR BLVD. WEST, QUEBEC, A8, H7L 4A8
Founded1994
BIOPHARMAWATCH ELITE PLUS
Trade the next BHC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime